January 25, 2021
DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Firm”) immediately introduced current senior management additions as a part of its international industrial technique. These embody: Elias Tu as Vice President of U.S. Gross sales; Derek Matteo as Vice President of Advertising and marketing; James Knibbs as Vice President of UK, Eire, and Australia; Boris Deutschmann as Nation Supervisor for Germany; Chip Moebus as Vice President of Reimbursement and Market Entry; Richard Herman as Vice President of Operations; and Celia Reyes as Vice President of Human Sources.
Previous to his new position at Mainstay, Elias Tu served as international industrial chief within the neurology division at Philips Healthcare. He additionally has over 13 years of gross sales expertise at LivaNova, a medical machine firm specializing in gadgets used for cardiac surgical procedure and neuromodulation. From 2016 to 2019, Mr. Tu served as Vice President of Gross sales for Neuromodulation in North America at LivaNova the place he attained $350 million in annual gross sales.
Since 2008, Derek Matteo has led International Advertising and marketing and International Business Improvement groups within the Orthopedic and Backbone healthcare trade. Most lately whereas at NuVasive, he served as Vice President of International Know-how Commercialization, scaling new improvements in the USA, Latin America, Europe, Australia, and throughout Asia.
James Knibbs brings in depth expertise in gross sales management in implantable gadgets. He was a Territory Gross sales Supervisor at Stryker Devices, adopted by a number of roles over roughly 9 years at Nevro. At Nevro, he rose from Enterprise Improvement Supervisor for North UK to UK Nation Supervisor, and ended his time there as Senior Space Director for Western Europe.
Boris Deutschmann possesses over 10 years of expertise within the Neuromodulation sector. Beforehand, he labored at Nevro for over six years, spending the latter a part of his time there as Nation Supervisor for Germany and Austria.
Chip Moebus has been within the well being care trade for over 20 years serving in a number of roles starting from discipline gross sales management to main groups centered on managed markets and well being economics at each Medtronic and Senseonics. Earlier than becoming a member of Mainstay Medical, he was a part of the senior management group at Senseonics the place he led industrial and Medicare protection and cost technique and execution for the primary implantable steady glucose monitor within the US market.
With over 20 years of discipline expertise in operations administration, Richard Herman contributes broad experience that might be important for the growth of operational actions at Mainstay. Beforehand, he served as Vice President of International Operational Excellence at Smith & Nephew, a British multinational medical machine firm. Mr. Herman beforehand held the place of Senior Director Lean Enterprise of International Operations at Alere, Inc., a world producer of speedy point-of-care diagnostic exams.
Celia Reyes possesses in depth international Human Sources expertise and information within the Life Sciences trade. She served as Govt Human Sources Director at Acadia Prescribed drugs, Inc., and beforehand labored as Govt Vice President of Human Sources at Biotix Holdings Inc., in addition to different key human sources positions at Millipore Sigma, Roche, and Solvay Prescribed drugs.
About Mainstay Medical Holdings
Mainstay Medical Holdings is a medical machine firm centered on commercializing an revolutionary implantable restorative neurostimulation system, ReActiv8®, for folks with disabling mechanical Power Low Again Ache (CLBP). The Firm is headquartered in Dublin, Eire and has subsidiaries working in Eire, the USA, Australia, Germany and the Netherlands.
ReActiv8 is an energetic implantable medical machine designed to deal with adults with intractable persistent low again ache related to dysfunction of the lumbar multifidus muscle, a key stabilizing muscle of the low again, as evidenced by imaging or physiological testing in adults who’ve failed remedy, together with ache medicines and bodily remedy, and are usually not candidates for backbone surgical procedure. ReActiv8 supplies bilateral electrical stimulation of the L2 medial department of the dorsal ramus nerve because it crosses the transverse course of at L3. This nerve provides the multifidus muscle to elicit contraction of the muscle which might result in restoration of management over time, permitting the again to recuperate from CLBP.
ReActiv8 has a CE Mark permitting for commercialization within the European Financial Space and has been centered on constructing medical validation in Germany in choose facilities forward of wider industrial availability. ReActiv8 has additionally been admitted to the Australian Register of Therapeutic Items (ARTG), enabling commercialization all through Australia, and has been permitted for inclusion on the Protheses Checklist of reimbursed merchandise in Australia, efficient as of 1 July 2020. The Prostheses Checklist identifies implantable gadgets eligible for reimbursement from all personal medical insurance funds in Australia. Within the U.S., ReActiv8 is FDA permitted and the Firm plans to commercially launch in early 2021.
About Power Low Again Ache
One of many root causes of CLBP is impaired management by the nervous system of the muscular tissues that dynamically stabilize the backbone. ReActiv8 is designed to electrically stimulate the nerves accountable for contracting these muscular tissues to enhance dynamic backbone stability, permitting for enchancment in CLBP and its disabling results.
Folks with CLBP normally have a vastly diminished high quality of life and rating considerably increased on scales for ache, incapacity, melancholy, nervousness and sleep issues. Their ache and incapacity can persist regardless of the perfect accessible medical remedies, and solely a small proportion of circumstances consequence from an recognized pathological situation or anatomical defect which may be correctable with backbone surgical procedure. Their potential to work or be productive is severely affected by the situation and the ensuing days misplaced from work, incapacity advantages and well being useful resource utilization put a big burden on people, households, communities, trade and governments.
Additional data may be discovered at www.mainstay-medical.com.
Ahead trying statements
This announcement consists of statements which can be, or could also be deemed to be, ahead trying statements. These ahead trying statements may be recognized by way of ahead trying terminology, together with the phrases “anticipates”, “believes”, “estimates”, “expects”, “intends”, “might”, “plans”, “initiatives”, “ought to”, “will”, or “discover” or, in every case, their damaging or different variations or comparable terminology, or by discussions of technique, plans, aims, targets, future occasions or intentions. These ahead trying statements embody all issues that aren’t historic info. They seem all through this announcement and embody, however are usually not restricted to, statements concerning the Firm’s intentions, beliefs or present expectations regarding, amongst different issues, the Firm’s plans to commercialize ReActiv8 in the USA, the U.Ok., Australia and elsewhere; the industrial efficiency of ReActiv8; and the Firm’s outcomes of operations, monetary place, prospects, financing methods, expectations for product design and growth, regulatory purposes and approvals, reimbursement preparations, prices of gross sales and market penetration and different industrial efficiency.
By their nature, ahead trying statements contain danger and uncertainty as a result of they relate to future occasions and circumstances. Ahead trying statements are usually not ensures of future efficiency, and precise outcomes might differ materially from these described in, or urged by, the ahead trying statements contained on this announcement. As well as, even when future outcomes and developments are according to the ahead trying statements contained on this announcement, these outcomes or developments is probably not indicative of outcomes or developments in subsequent intervals. Various elements may trigger outcomes and developments of the Firm to vary materially from these expressed or implied by the ahead trying statements, together with, with out limitation, the profitable launch and commercialization of ReActiv8, the supply and value of capital, normal financial and enterprise circumstances, international medical machine market circumstances, trade tendencies, competitors, adjustments in regulation or regulation, adjustments in taxation regimes, the time required to start and full medical trials, the time and course of required to acquire regulatory approvals, forex fluctuations, adjustments in its enterprise technique, and political and financial uncertainty. The forward-looking statements herein communicate solely on the date of this announcement.
PR and IR Enquiries:
LifeSci Advisors, LLC
Tel: + 1 (212) 915-2578
Electronic mail: firstname.lastname@example.org
FTI Consulting (for Eire)
Jonathan Neilan or Patrick Berkery
Tel. : +353 1 765 0886
Electronic mail: email@example.com
The Ruth Group
Tel: +1 (720) 412-9042
Electronic mail: firstname.lastname@example.org